Biomanufacturing for clinically advanced cell therapies
Ayesha Aijaz(University of Oklahoma Health Sciences Center), Biju Parekkadan(Rutgers, The State University of New Jersey), Jerome Ritz(Dana-Farber Cancer Institute), Owen S. Fenton(Teagasc - The Irish Agriculture and Food Development Authority), Jay A. Tischfield(Rutgers, The State University of New Jersey), Ronke M. Olabisi(Rice University), Marcela V. Maus(Center for Cancer Research), Daniel G. Anderson(Massachusetts Institute of Technology), Courtney LeBlon, Danika Khong(Harvard University), David Smith(Loughborough University), Rita N. Bárcia(Sentien (United States)), Robert Deans(Rubius Therapeutics (United States)), Matthew Li(Harvard University), Robert A. Preti(Neostem (United States)), Steven K. Libutti(Unknown)
Cited by 191
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Knocking down barriers: advances in siRNA delivery
|Nature Reviews Drug Discovery|2009|3.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k